PCNA Bearing Structures are Retained in Apoptotic Phase of Childhood All Cell Cycle

Author(s):  
Lynne M. Ball ◽  
Christopher L. Lannon ◽  
Margaret Yhap ◽  
Allen F. Pyesmany ◽  
M. Henry ◽  
...  
Keyword(s):  
1982 ◽  
Vol 6 (4) ◽  
pp. 323-330 ◽  
Author(s):  
Nyla A. Heerema ◽  
Catherine G. Palmer ◽  
Robert L. Baehner

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4231-4231
Author(s):  
Dong Kyun Han ◽  
Li Yu ◽  
Huong Thi Thanh Tran ◽  
Hee Nam Kim ◽  
Il Kwon Lee ◽  
...  

Abstract Abstract 4231 Background: Recent genomic studies have analyzed genetic alterations and gene expression in childhood acute lymphoblastic leukemia (ALL), and detected multiple new submicroscopic genetic abnormalities in key cellular pathways, and also identified new prognostic markers and therapeutic targets. More than 50 recurring genetic alterations have been identified, and these genes are known to play key or putative roles in lymphoid development and leukemogenesis. Multiplex Ligation-dependent Probe Amplification (MLPA) is a rapid multiplex PCR based technique that allows the comparative quantification of multiple sites. However, there have been no reports on the MLPA based copy number alterations (CNA) of childhood ALL in Asian countries. The aim of this study is to reveal the CNA of genes involved in lymphoid differentiation and cell cycle control in Korean children with ALL. Patients and Methods: Reference ranges for individual MLPA probes were established from a group of 30 healthy control subjects. The MLPA assay was performed for 121 children with ALL in Korea to target those genes including the lymphoid differentiation genes (BTG1, EBF1, IKZF1, and PAX); cell cycle control genes (CDKN2A/B and RB1); transcriptional factors regulating genes (ETV6); and those deleted from the PAR1 region (IL3RA, CRLF2 and CSF2RA). We also evaluated the prognostic impact of these abnormalities. Results: Out of the 121 patients analyzed in our study, 96 (79%) displayed CNA in at least one gene: PAX5, 49 (40%); CDKN2A, 42 (35%); CDKN2B, 35 (29%); IKZF1, 22 (18%); ETV6, 22 (18%); EBF1, 16 (13%); RB1, 16 (13%); BTG1, 14 (12%); CRLF2, 12 (10%); IL3RA, 12 (10%); CSF2RA, 11 (9%). Thirteen of 121 (11%) patients relapsed. There was no significant correlation between these CNA and the recurrence of ALL. Conclusion: These results suggest that CNA of PAX5, CDKN2A/B may play an important role in the pathogenesis of childhood ALL in Korea, contrasting to those findings from western countries showing a significant correlation between IKZF1 and childhood ALL. Several factors should be considered to explain a discrepancy between our results and the previous studies, which include different genotype frequencies in polymorphisms and varied susceptibility to ALL in different ethnic groups. Further studies incorporating larger number of cases and analyzing other possible genes are warranted in childhood ALL. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 791-791 ◽  
Author(s):  
Jun J. Yang ◽  
Heng Xu ◽  
Deepa Bhojwani ◽  
Takaya Moriyama ◽  
Maoxiang Qian ◽  
...  

Abstract Acute lymphoblastic leukemia (ALL) in children is a prototype of cancer that can be cured by chemotherapy alone. However, the molecular mechanisms for anti-leukemic drug sensitivity and genetic basis of inter-patient variability in treatment response are not fully understood. Taking a genome-wide approach, we recently identified genetic variants in the ARID5B gene that strongly predispose children to developing ALL and also a high risk of relapse following therapy (J Clin Oncol 2012 30:751, Nat Genet 2009 41:1001). To understand the mechanisms by which ARID5B is linked to treatment outcome in childhood ALL, we sought to 1) characterize ARID5B expression in different genetic subtypes of ALL, 2) determine the effects of ARID5B expression on cytotoxicity of chemotherapeutic agents commonly used in ALL therapy, and 3) describe molecular pathways linking ARID5B to anti-leukemic drug sensitivity. In 567 children with newly diagnosed ALL treated at St. Jude Children’s Research Hospital (GSE33315), ARID5B expression was highest in cases with hyperdiploid karyotype (>50 chromosomes) and lowest in T-cell ALL and cases with MLL rearrangements. This pattern was validated in an independent cohort of 106 children from the Dutch Childhood Oncology Group (GSE13351). In 59 patients treated on the Children’s Oncology Group (COG) CCG1961 trial, lower ARID5B expression was associated with higher rates of relapse (P=0.01, GSE7440). Importantly, when we compared matched newly-diagnosed vs. relapsed ALL blasts from a cohort of 60 patients enrolled in COG trials (GSE28460), ARID5B expression was further downregulated at disease recurrence (P=0.0009). shRNA-mediated ARID5B knockdown in 3 ALL cell lines (Nalm6, SEM, and UOCB-1) substantially increased resistance to antimetabolites (an average of 5.16 and 35.3-fold increase in IC50 for methotrexate [MTX] and 6-mercaptopurine [6MP], respectively), with minimal effects on glucocorticoids, vincristine, asparaginase, and daunorubicin. Because cytotoxic effects of MTX and 6MP are highly dependent on the rate of cell proliferation, we postulate that ARID5B directly influences cell cycle entry. In all 3 cell lines, ARID5B knockdown led to significant blockade at the G1/S checkpoint, increasing the percent of cells in G0/G1 phase. At the molecular level, downregulation of ARID5B resulted in higher levels of p21 and reduction in phosphorylated Rb, consistent with the retention at G0/G1 phase. ARID5B expression was restricted to nucleus but affected both nuclear and cytoplasmic p21 expression in a time-dependent fashion. Interestingly, there was a highly significant negative correlation between p21 expression and MTX- and 6MP-induced apoptosis in all 3 ALL cell lines. Taken together, we hypothesize that lower expression of ARID5B impairs ALL cell cycling by upregulating p21, contributing to resistance to MTX and 6MP and eventually leukemia relapse. Finally, we compared global gene expression in ARID5B knockdown vs. control ALL cells, and via the Connectivity Map analysis we identified histone deacetylase (HDAC) inhibitors as promising agents for overcoming ARID5B-related drug resistance. Indeed, ARID5B knockdown cells were significantly more sensitive to panobinostat than controls, suggesting HDAC inhibitors as potential therapeutic options for patients with ARID5B-deficient and drug resistant ALL. Disclosures No relevant conflicts of interest to declare.


Leukemia ◽  
2007 ◽  
Vol 21 (6) ◽  
pp. 1258-1266 ◽  
Author(s):  
R P Kuiper ◽  
E F P M Schoenmakers ◽  
S V van Reijmersdal ◽  
J Y Hehir-Kwa ◽  
A Geurts van Kessel ◽  
...  

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 155-155
Author(s):  
Maria Rosaria Ricciardi ◽  
Chiara Gregorj ◽  
Fabiana De Cave ◽  
Paola Bergamo ◽  
Samantha Decandia ◽  
...  

Abstract The treatment of adult acute lymphoblastic leukemia (ALL) remains unsatisfactory. A potential hope is now given to Philadelphia-positive cases by targeted treatment modalities. Among other pathways involved in cell proliferation, we have recently demonstrated (Blood2007; 109:5473) the unfavorable role of ERK1/2 phosphorylation as an independent predictor of complete remission (CR) in adult ALL, suggesting the potential therapeutic value of other targeted therapies. The B-cell leukemia/lymphoma 2 (Bcl-2) family of proteins are important regulators of apoptosis and are frequently found aberrantly expressed, particularly in lymphoid malignancies. The role of Bcl-2 overexpression in tumorigenesis and chemoresistance prompted us to investigate whether the inhibition of the antiapoptotic function may result also in ALL in an attractive therapeutic strategy. In this study, we thus investigated the cell cycle and apoptotic effects of ABT-737 (kindly provided by Abbott Laboratories), a Bcl-2 (BH3) inhibitor, on both lymphoid leukemia cell lines and primary adult and childhood ALL cells. The lymphoid leukemia cell lines CEM and MOLT-4 were exposed to increasing concentrations of ABT-737 (from 0.1 to 1 μM) up to 72 hours. A dose- and time-dependent cell growth arrest and induction of apoptosis was found. In fact, measuring the subG0/1 peak at 48 hours, the levels of apoptosis increased in the CEM cell line from 14.1% (DMSO) to 34.4%, 64.5%, 86.5% and 98.6% at ABT-737 concentrations of 0.1, 0.25, 0.5 and 1 μM, respectively. Similarly, 48 hours of exposure to ABT-737 increased in MOLT-4 the Annexin V-positive cells from 7.2% to 64.2%. The effects of ABT-737 were then examined on primary blasts from 9 ALL patients (6 adults and 3 children). Bone marrow aspirates with a blast infiltration >70% were obtained at diagnosis from patients broadly characterized for clinical and biological parameters, as well as therapeutic response. ALL cells were cultured in vitro with ABT-737 (at increasing concentrations from 0.01 to 1 μM) for 24 hours. A significant decrease in viability was observed at 0.01 μM (p=0.008) with a remarkable dose-dependent increase of apoptosis. In fact, Annexin V-positive cells increased from a mean baseline value of 16.8% ± 8.8 to 43.6% ± 22.8 (p=0.04), 66% ± 21.3 (p=0.0001), 70.3% ± 26.9 (p=0.04), 74.6% ± 18.9 (p=0.03) and 76.2% ± 11.8 (p<0.0001) in the presence of ABT-737 at 0.01, 0.1, 0.25, 0.5 and 1 μM, respectively. A significant cell killing was demonstrated in all samples (9/9), including Ph-positive ALL. No significant cell cycle changes were instead detected even at higher concentration of ABT-737. In summary, our study shows for the first time a potent growth-inhibitory and pro-apoptotic activity of the Bcl-2 antagonist ABT-737, at nanomolar concentrations, on primary cells from adult and childhood ALL samples. These results prompt to further extend pre-clinical studies in the different biologically-defined subset of ALL and suggest a potential clinical development of a Bcl-2 family inhibitor in this disease.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1585-1585
Author(s):  
Christoph Lutz ◽  
Petter Woll ◽  
Anders Castor ◽  
Helen Ferry ◽  
Christina Jensen ◽  
...  

Abstract Abstract 1585 Recent studies utilising surrogate leukaemic stem cell (LSC) assays have suggested that LSCs in acute lymphoblastic leukaemias (ALLs) might be neither rare, nor phenotypically or functionally distinct. However, studies of candidate LSCs in surrogate assays might not recapitulate the full leukaemic potential of candidate LSCs in patients, and in particular their responsiveness and resistance to therapeutic targeting. Therefore, we have investigated the identity, molecular and functional properties, and persistence of different subsets of candidate LSCs in childhood ALL, at diagnosis and during the course of clinical and molecular remissions in response to chemotherapy, and their relationship to subsequent relapses. First, we investigated 6 patients diagnosed with “good prognosis” TEL-AML1+ ALL, and at diagnosis we found TEL-AML1+ leukaemic cells within the immature B cell progenitor compartment (proB: 34+38+19+), mature B-cells (34-19+), as well as in a population expressing an aberrant combination of stem cell (34+38-/lo) and B-cell (19+) cell surface markers. These stem/B (34+38-/lo19+) cells were all TEL-AML1+ and not present in age-matched normal bone marrow controls. In contrast, haematopoietic stem cells (HSC: 34+38-19-) were not part of the TEL-AML1+ leukaemic clone in any of the patients. 15 days into chemotherapy, all TEL-AML1+ mature B-cells were eliminated in all patients, and this was followed by a clearance of leukaemic proB cells by day 28 of treatment. In striking contrast, leukaemic stem/B cells were still detectable at day 28, but in all TEL-AML1 patients, at later stages all leukaemic cells including the stem/B cells were undetectable, and at the same time these patients went into complete remission with less than 1 leukaemic cell in 10e4 cells detectable. A similar pattern was observed in a case of “high risk” BCR-ABL+ ALL: BCR-ABL+ proB and B-cells were efficiently eliminated by day 90 of the course of chemotherapy, and up to 180 days into the treatment only 34+38-/lo19+ stem/B cells remained part of the BCR-ABL+ clone. In agreement with the persistence of BCR-ABL+ 34+38-/lo19+ stem/B cells, this patient relapsed 17 months after the initiation of chemotherapy. In order to understand the underlying mechanisms of the observed functional and therapeutic heterogeneity seen in leukaemic subpopulations, we performed comparative gene-expression analysis of diagnostic leukaemic stem/B and proB cells of TEL-AML1+ patients. This analysis revealed a differential gene expression pattern between leukaemic stem/B and proB cells, with positive regulators of cell cycle being the most distinctly up regulated genes in leukaemic proB cells. In agreement with this, cell cycle analysis of 3 diagnostic TEL-AML1+ cases also showed proB cells to be more actively cycling compared to the more quiescent state of the leukaemic stem/B compartment (proB: G0 42%; G1 40%; S,G2,M 18% vs. stem/B: G0 81%; G1 18%; S,G2,M 1%), providing a potential mechanistic basis for the relative therapy resistance of ALL stem/B cells. Taken together the present studies suggest that quiescent 34+38-/lo19+ stem/B cells are selectively resistant to chemotherapy, and most likely the origin of relapses when these occur in childhood ALL. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 3539-3539 ◽  
Author(s):  
Inés Gómez-Seguí ◽  
Esperanza Such ◽  
Jose Cervera ◽  
Pascual Fernandez ◽  
Lurdes Zamora ◽  
...  

Abstract Abstract 3539 Background: Microdeletions of genes involved in B lymphopoiesis and cell-cycle regulation, such as CDKN2A/B, PAX5, IKZF1, ETV6, RB1, BTG1 and EBF1 have been reported as a frequent event in pediatric acute lymphoblastic leukemia (ALL). Whether these findings are found in adulthood and the possible differences with childhood ALL, as well as its prognostic implication, are still unknown. Aims: To assess the differences between two cohorts of children and adults diagnosed with ALL on the frequency of deletions in these genes and their relationship with clinical data and prognosis. Methods: We studied 70 children and 83 adults diagnosed with ALL with available DNA sample at diagnosis. In children, median age was 4y. (1 – 14), median leukocytes 10.3×109/L (0.7 – 675) and the cytogenetic risk distribution was 42(39%), 30(27%) and 12(11%) for favourable [t(12;21) and hyperdiploidy], intermediate (normal karyotype and miscellaneous) and high risk [t(9;22), t(4;11), hypodiploid and complex karyotype], respectively. In adults, median age was 38y. (15 – 85), median leukocytes 16.8×109/L (1 – 371) and 29(35%) patients belonged to the high risk cytogenetic group. We performed Multiplex Ligation Probe Amplification (MLPA) using SALSA kit P335-A1 (MRC-Holland). PCR products were separated on an ABIPRISM 310 DNA Analyzer and analyzed using GeneMapper v3.2 (Applied Biosystems). Results: Frequency of deletions in the studied genes was similar in children and adults, except for IKZF1 deletions that were more frequent in adults (P<.001) (Table 1). In children, ETV6 deletions occurred more frequently in patients with t(12;21) (67% of patients with deletion vs. 17% without, P <.001); CDKN2A/B deletions were found in patients assigned to the intermediate cytogenetic risk group (59% of patients with deletion vs. 23% without, P =.028); and the three cases with RB1 deletions were found in patients with hypodiploidy (P <.001). In adults, ETV6 and CDKN2A/B deletions occurred more frequently in women (67% vs. 39%, P =.022 and 77% vs. 42%, P =.021, for patients with and without deletions, respectively); PAX5 and IKZF1 deletions appeared more frequently in patients with >30×109/L leukocytes (60% vs. 27%, P =.032 and 52% vs. 21%, P =.007, for patients with and without deletions, respectively); besides, PAX5 deletions occurred in patients who belonged to the standard cytogenetic risk group (55% vs. 6% for patients with and without deletions, P <.001). In the pediatric cohort, the leukocytes >30×109/L and the cytogenetic risk group were the variables that reached statistical significance for both overall survival (OS) and relapse free survival (RFS) and also age >10y. for OS, but in the multivariate analyses, just the cytogenetic risk classification remained significant [HR: 4 (CI 95%: 1.6 – 10), P =. 004 for OS and HR: 3.5 (CI 95%: 1.7 – 7.2), P =. 001 for RFS]. In the adult cohort, multivariate analysis for OS including all significant variables in the univariate analysis (age >60y, karyotype, CDKN2A/B and ETV6 deletions) showed as independent variables: age >60y. [HR: 4.3 (CI 95%: 2.1 – 8.6), P<. 001] and CDKN2A/B deletions [HR: 2.6 (CI 95%: 1.4 – 5.3), P=. 004]. Similarly, taking into account karyotype, CDKN2A/B and ETV6 deletions for the RFS multivariate analyses, just ETV6 deletions arose as an independent factor [HR: 3.8 (CI 95%: 1.5 – 9.4), P=. 004]. In fact, having CDKN2A/B and/or ETV6 deletions conferred a worse prognosis to patients in both standard risk cytogenetic group (3y. RFS: 45% vs. 70% for patients with and without deletions, respectively; P =.049) and high risk cytogenetic group (3y. RFS: 14% vs. 66% for patients with and without deletions, respectively; P =.025). Conclusions: This study shows the high incidence of deletions in genes of cell-cycle and B-lymphopoiesis in adult and pediatric ALL. However, the biological and prognostic implications of these deletions seem to differ between both patient groups: while cytogenetics was the strongest variable for risk assessment in children, gene microdeletions in CDKN2A/B and ETV6 added a prognostic value to karyotype in our adult cohort. Fundings: AP-194/10, R06/0020/0031, BES2008–008053, CM10/00321, CM09/00038, and CA08/00141. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 2087-2087
Author(s):  
Julio C. Barredo ◽  
Sanja Altman-Hamandzic ◽  
Guy J. Leclerc

Abstract Methotrexate (MTX) is a universal component of chidlhood ALL therapies and its conversion to long chain polyglutamates (PG) by folylpoly-γ-glutamate synthetase (FPGS) is essential for its antileukemic acitivity. Expression of FPGS appears to be controlled by tissue/lineage specific and proliferation-dependent mechanisms. Levels of FPGS mRNA, protein, and enzyme activity are 2-3 fold higher in B-precursor (Bp) ALL cells when compared to T-lineage ALL, and these differences correlate with intracellular accumulation of long chain MTX-PG and lymphoblast sensitivity to MTX. To characterize these lineage differences in FPGS expression between B and T lymphoblasts we examined its mRNA expression in Nalm6 (Bp-ALL) and CCRF-CEM (T-ALL) cells during cellular growth and cell cycle checkpoints. During early exponential growth (24 hrs), FPGS expression was 6-fold higher in Nalm6 when compared to CCRF-CEM but decreased significantly after 72 hrs while it was unchanged in CCRF-CEM cells. During G1/G0 phase we found that FPGS expression was 15-fold higher in Nalm6 when compared to CCRF-CEM cells. Taken together, these data suggest that during proliferation and cell cycle progression FPGS gene expression is regulated differently in Bp-ALL and T-ALL cells. To determine whether this lineage-specific regulation occurs at the transcriptional level we performed nuclear run-on assays. We found that FPGS mRNA transcription initiation rate was 1.7-fold higher in Nalm6 when compared to CCRF-CEM cells, indicating that differences in promoter regulation lead to the observed lineage differences in FPGS expression in Bp- vs. T-ALL. We then used a methylation specific PCR assay to investigate the methylation status of the FPGS proximal promoter region from both Nalm6 and CCRF-CEM cells. Our data indicate that the FPGS proximal promoter region is unmethylated in both cell lines and therefore can not explain the observed lineage-specific differences. 5′-RACE experiments demonstrated that Nalm6 and CCRF-CEM have the same FPGS transcriptional start sites, but a reporter gene assay indicated that the minimal promoter region that directs FPGS transcription in CCRF-CEM cells is insufficient to drive FPGS mRNA transcription in NALM6 cells. In order to identify potential regulatory regions directing FPGS transcription in Bp-lymphoblasts, we used DNaseI hypersensitivity assays. We identified a hypersensitive region located 8.5 kbp upstream to exon 1 in Nalm6 cells suggesting that tissue-specific regulatory elements responsible for lineage-specific FPGS expression in Bp-ALL cells may be localized within this region. Finally, we detected reduced levels of FPGS mRNA expression in RCH-ACV (Bp-ALL, t(1:19)/E2A-PBX1) and REH (Bp-ALL, t(12:21)/TEL-AML1) cells expressing chromosomal translocated fusions when compared to control (Nalm6). To characterize the molecular basis of the E2A-PBX1 and TEL-AML1 interactions with FPGS mRNA expression in Bp lymphoblasts we used antisense and RNAi technology to downregulate these two genetic fusions. Our data lead us to hypothesize that in addition to lineage-specific regulatory differences in FPGS expression, molecular mechanisms associated with non-random translocations may alter FPGS mRNA expression and influence MTX sensitivity in Bp-ALL lymphoblasts.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 2467-2467 ◽  
Author(s):  
Patrick Brown ◽  
Mark Levis ◽  
Emily McIntyre ◽  
Melissa Griesemer ◽  
Donald Small

Abstract Rearrangement of the MLL gene at chromosome 11q23, which occurs in 80% of infants and 5% of older children with acute lymphoblastic leukemia (ALL), confers a dismal prognosis despite maximally intensified chemotherapy and allogeneic transplantation. Novel therapies are clearly needed for these patients. The FLT3 tyrosine kinase represents an attractive potential target in these leukemias, due to the marked overexpression of FLT3 in cases of MLL-rearranged ALL. We have previously shown that MLL-rearranged infant and childhood ALL leukemic cells express high levels of constitutively activated FLT3 receptor protein, and that these cells are selectively killed by exposure to the FLT3 inhibitor CEP-701. However, FLT3 inhibition is unlikely to represent curative therapy for these patients if used as monotherapy. Thus, we examined various combinations of CEP-701 with chemotherapy to look for potentially synergistic therapeutic strategies. We performed MTT cytotoxicity and annexin V binding (AVB) apoptosis assays on MLL-rearranged ALL cell lines (SEM-K2 and HB-1119) and three primary patient samples (all of which we show to express high levels of constitutively activated FLT3) after exposure to multiple dose combinations of CEP-701 and six chemotherapy agents (vincristine, l-asparaginase, dexamethasone, daunorubicin, etoposide and cytarabine). Since we have previously demonstrated that the nature of the interactions between CEP-701 and chemotherapy agents (i.e., synergistic, additive or antagonistic) are sequence-dependent in AML cells, we performed the MTT and AVB assays in three sequences designed to mimic the potential clinical uses of the combinations (Seq1: chemotherapy followed by CEP-701; Seq2: simultaneous exposure to both; and Seq3: CEP-701 followed by chemotherapy). The nature of the interaction between CEP-701 and each chemotherapy agent was determined using the median effect method of Chou and Talalay, which calculates a combination index (CI) for each combination (CI &lt; 0.9 - synergistic; CI 0.9-1.1 - additive; CI &gt; 1.1 antagonistic). A striking pattern of sequence-dependent synergy was observed: Seq1 was markedly synergistic (mean CI +/− SD = 0.59 +/− 0.18), Seq2 was additive (CI = 0.99 +/− 0.29) and Seq3 was antagonistic (CI = 1.23 +/− 0.40). The sequence-dependence is attributable to the G1 cell cycle arresting effects of CEP-701 in these cells. An MLL-rearranged cell line that expresses low levels of minimally activated FLT3 (RS4-11) demonstrates minimal cell cycle arrest when treated with CEP-701, and mere additivity in all 3 CEP-701/chemotherapy combination sequences (Seq1: CI = 0.95 +/− 0.10; Seq2: CI = 1.01 +/− 0.09; Seq3: CI = 1.06 +/− 0.10), confirming that the observed pattern of synergy is mediated through the effects of CEP-701 on FLT3 signaling. These results can help guide the combination of CEP-701 with existing chemotherapy regimens for infants and children with MLL-rearranged ALL, with the goal of improving the dismal outcome for these patients.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2500-2500
Author(s):  
Gregory Miles ◽  
Gunaretnam Rajagopal ◽  
Roger Strair ◽  
Hatem E Sabaawy

Abstract Abstract 2500 Despite high cure rates for childhood ALL, treatment failure remains a formidable problem. TEL-AML1 (ETV6-RUNX1), the product of t (12;21) translocation, is the most common cytogenetic abnormality in childhood cancer, and is detected in 25–30% of precursor B-cell (pre-B) acute lymphoblastic leukemia (ALL) in children, and in small percentage of adult ALL. Considerable experimental and clinical evidence indicate that the TEL-AML1 fusion is insufficient by itself for leukemic transformation. First, monozygotic twins had the same prenatal TEL-AML1 sequence, but different latency and/or no leukemia development. Second, we have previously established transgenic zebrafish expressing TEL-AML1. These TEL-AML1 transgenic zebrafish have hematopoietic stem cell (HSC) expansion, and develop pre-B ALL at low penetrance, and after prolonged latency. Similarly, transgenic mice expressing TEL-AML1 did not develop pre-B ALL, but showed HSC expansion. Third, retroviral-mediated TEL-AML1 gene transfer into murine HSCs resulted in a preleukemic state, and the incidence of leukemia increased with additional mutation. Here, we report on the identification of a TEL-AML1-specific leukemic signature in ALL cases, and modeling of these mutations in dual and compound transgenic zebrafish. First, we performed meta-analyses of ÓALL compendiumÕ of molecular signatures and expression profiles of 990 ALL cases from six studies, measuring the expression of 14,145 genes in 475 arrays. The normalized data were imported into the Ingenuity Pathway Analysis (IPA) software to identify TEL-AML1-related pathways. We determined a TEL-AML1-specific signature that was organized into modules that are induced or suppressed, based on involvement in several biological pathways comprising the hallmarks of cancer. These analyses identified modules of cell differentiation, cell proliferation, apoptosis, autophagy, cell cycle regulation, and lymphocyte development as the most common modules associated with TEL-AML1. The signature was confirmed using additional microarray analyses, in combination with Q-PCR, and western blotting from the same cases. Similar analyses of marrow cells from transgenic zebrafish with ALL identified 1,128 upregulated and 936 down-regulated genes with 27 genes common with the human TEL-AML1 signature. We next isolated the zebrafish homologues of several induced signature genes to generate dual and compound transgenic zebrafish, and to investigate the effects of their overexpression on TEL-AML1 leukemia development. Analyses of established transgenic fish demonstrate leukemia-enhancing effects of signals within the proliferation and cell cycle modules. These studies provide a model to understand the role of the TEL-AML1 fusion and the secondary mutations required for leukemia development, and might present a rational for leukemia combination therapy. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document